Are the cardiovascular properties of GLP-1 receptor agonists differentially modulated by sulfonylureas? Insights from post-hoc analysis of Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
Authors' conclusion
SUs did not modulate the effect of EQW on cardiovascular outcomes, suggesting that SU treatment choices need not be altered to optimize the cardiovascular effects of GLP-1 receptor agonists in people with type 2 diabetes.
Study context
- Population
- All EXSCEL trial participants with T2D, categorized as sulfonylurea (SU) users or nonusers
- Comparison
- Once-weekly exenatide vs placebo, by SU use and SU type
- Primary endpoint
- MACE (time to MACE), EQW effect by SU use and baseline SU type
Methodological detailspost-hoc analysis, intent-to-treat analyses, marginal structural models
- Post-hoc analysis
- Intent-to-treat analyses
- Marginal structural models
Primary result
As reported in the abstract
Time to MACE: modification of EQW effect by SU use and baseline SU type
- Neither SU use nor baseline SU type modified the effect of EQW on time to major adverse cardiovascular events (MACE), nor did individual SU types, including glibenclamide
- EQW vs Placebo: P for interaction = 0.88
- EQW vs Placebo: P for interaction = 0.78
- Intent-to-treat analyses
- Post-hoc analysis
Original publication
Are the cardiovascular properties of GLP-1 receptor agonists differentially modulated by sulfonylureas? Insights from post-hoc analysis of EXSCEL. Diabetes Res Clin Pract. Published 25 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →